Arch Therapeutics, Inc (OTCQB:ARTH) Revenue and Competitors
Estimated Revenue & Valuation
- Arch Therapeutics, Inc (OTCQB:ARTH)'s estimated annual revenue is currently $1.7M per year.
- Arch Therapeutics, Inc (OTCQB:ARTH)'s estimated revenue per employee is $155,000
- Arch Therapeutics, Inc (OTCQB:ARTH)'s total funding is $20.9M.
Employee Data
- Arch Therapeutics, Inc (OTCQB:ARTH) has 11 Employees.
- Arch Therapeutics, Inc (OTCQB:ARTH) grew their employee count by 57% last year.
Arch Therapeutics, Inc (OTCQB:ARTH) Competitors & Alternatives
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | -94% | N/A | N/A |
#2 | $2.6M | 17 | N/A | N/A | N/A |
#3 | $6M | 39 | -20% | $176.5M | N/A |
#4 | $4.5M | 29 | N/A | N/A | N/A |
#5 | $2.6M | 17 | N/A | N/A | N/A |
#6 | N/A | 145 | -21% | $39.5M | N/A |
#7 | N/A | 0 | N/A | $9.5M | N/A |
#8 | $15.9M | 159 | -39% | $135M | N/A |
#9 | $1.7M | 11 | 57% | $20.9M | N/A |
#10 | $2.8M | 18 | 50% | $28.9M | N/A |
What Is Arch Therapeutics, Inc (OTCQB:ARTH)?
Arch Therapeutics, Inc. (OTCQB:ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5® Advanced Wound System and AC5® Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G™, AC5-V® and AC5® Surgical Hemostat, among others.1,2 1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use. 2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.
keywords:N/A$20.9M
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
57%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Arch Therapeutics, Inc (OTCQB:ARTH) News
FRAMINGHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (Arch or the Company), a marketer and...
(OTCQB: ARTH) (Arch or the Company), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced...
FRAMINGHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (Arch or the Company), a marketer and...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.8M | 12 | N/A | N/A |
#2 | $3M | 12 | N/A | N/A |
#3 | $2M | 14 | N/A | N/A |
#4 | $1.3M | 15 | N/A | N/A |
#5 | $2.2M | 16 | 23% | N/A |